Biopharma and Medtech are leading the fight against COVID-19, but are not immune from the significant economic impact of the pandemic.
The COVID-19 pandemic is having a devastating effect on global health and economies, and the biopharma and medtech sectors are under pressure to produce solutions at record speed.
The new Evaluate Vantage COVID-19 Report examines the progress so far, to identify which treatments and vaccines are of most interest in the fight against the virus. It also examines the wider effect the pandemic is having on the sector, including share price declines, the potential financial implications of disruption and the cost of delays, as well as the deals being triggered by the crisis.
Download your copy of the Evaluate Vantage COVID-19 Report to understand the coronavirus’s impact on biopharma, and the sector’s response.